Com­mu­ni­cat­ing the val­ue of pre­ci­sion med­i­cine

6 days ago

Prac­ti­cal im­pli­ca­tions of re­cent FDA guid­ance on im­muno­genic­i­ty risk as­sess­ments on your IND sub­mis­sions

3 weeks ago

RWE chal­lenges for to­day's bio­phar­ma

4 weeks ago

Med­ical an­i­ma­tion: Mak­ing it eas­i­er for the site and the pa­tient to un­der­stand

Last month

Novotech CRO sees 26% growth in Asia tri­al ac­tiv­i­ty from biotechs, but still plen­ty of ca­pac­i­ty

Last month

The next 10 years: Where is biotech head­ed?

Last month

Lead­ing the Next CAR T Rev­o­lu­tion in Can­cer

Last month

Solv­ing the chal­lenge of nu­cle­ic acid de­liv­ery in RNA med­i­cines

3 months ago

Novotech CRO Ex­pands Chi­na Team as Biotech De­mand for Clin­i­cal Tri­als In­creas­es up to 79%

4 months ago

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

4 months ago

How small- to mid-sized biotechs can adopt pa­tient cen­tric­i­ty in their on­col­o­gy tri­als

5 months ago

De­liv­er­ing CNS-fo­cused pa­tient in­no­va­tions

5 months ago

Boost­ing check­point in­hibitor ef­fi­ca­cy via the mi­cro­bio­me

6 months ago

How the sur­gi­cal set­ting con­tributes to the opi­oid cri­sis

8 months ago

Fol­licum, a Swedish biotech com­pa­ny born to find a treat­ment for hair loss, now has di­a­betes in its crosshairs

8 months ago

Ap­ta­hem – a Swedish biotech aim­ing to win the race against sep­sis

10 months ago

Fo­cus on tar­get­ed val­ue cre­ation and in­creased strate­gic man­age­ment is key to ad­dress chal­lenges with R&D bio­phar­ma­ceu­ti­cal pre­c­om­pet­i­tive col­lab­o­ra­tions

11 months ago

Io­n­is is fo­cused on treat­ing the un­treat­able with med­ical break­throughs for pa­tients

11 months ago

Cereno Sci­en­tif­ic is dri­ving a new par­a­digm of throm­bo­sis pre­ven­tion with­out as­so­ci­at­ed bleed­ing-risks

11 months ago

Nov­el he­pati­tis B virus nu­cle­o­cap­sid for­ma­tion in­hibitor CB-HBV-001 demon­strates ex­cel­lent an­ti-HBV ac­tiv­i­ty

Last year

How tri­al in­no­va­tion in Aus­tralia is get­ting ther­a­pies to pa­tients soon­er

Last year

With ac­cess to 1.4 bil­lion po­ten­tial Asia-Pa­cif­ic tri­al par­tic­i­pants, Novotech CRO can help get your drug to mar­ket faster

Last year

PPD Biotech pan­el: Five biotech lead­ers of­fer their sur­pris­ing takes on the big trends shap­ing the in­dus­try in the Bay Area and be­yond

Last year

A Swedish biotech is tar­get­ing throm­bo­sis us­ing the body's own de­fense sys­tem to pre­vent blood clots with low­er risk of bleed­ing as­so­ci­at­ed with cur­rent an­tithrom­bot­ic ther­a­pies

Last year
12 Next page Last page